Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients

[1]Alicia Lichvar, [2,3]Simon Tremblay, [4]Devanshi Naik, [5]Jessi Lipscomb, [5]Eileen King, [6]Alexander A. Vinks, [7]Uwe Christians, [8]Rita R. Alloway

[1]Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL; [2]Department of Surgery, Division of Transplantation, University of Cincinnati, Cincinnati, OH; [3]Department of Environmental Health, Division of Epidemiology, University of Cincinnati, OH; [4]University of Cincinnati, James L. Winkle College of Pharmacy, Cincinnati, OH; [5]Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; [6]Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; [7]Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Denver, CO; [8]Department of Internal Medicine, Division of Nephrology, University of Cincinnati, Cincinnati, OH

UNIVERSITY OF Cincinnati

Background

The use of generic tacrolimus has remained controversial despite numerous studies. In previous evaluations, conversion from innovator to generic was often accomplished in a highly-controlled environment, including prompt trough level follow-up and stringent prospective monitoring. Despite similar allograft function and tacrolimus trough levels in these studies, dose changes were observed in up to 21% of transplant recipients after conversion, with authors suggesting a role for closer tacrolimus level monitoring after switching between manufacturer tacrolimus products. However, none of these conversion studies included control arms in which patients remained solely on either innovator or generic tacrolimus throughout the study period to serve as comparator groups.

The purpose of this retrospective study was to compare clinical and safety outcomes of transplant recipients who were converted between different tacrolimus products to those who were not converted between different formulations in an uncontrolled environment with no pre-defined monitoring protocols.

Methods

- A retrospective, non-randomized single center study of transplant recipients at the University of Cincinnati Medical Center with pharmacy refill data from August 2009 to May 2016. This study was a component of the FDA Solicitation 13-223-SOL-00102 to review tacrolimus conversion in a high-risk population.

- Patient population:
  - Inclusion: adult (> 18 years), 2 years of pharmacy refill data, > 6 months post-transplant, had tacrolimus conversion at least > 1.5 years from transplantation (for those in the conversion groups)
  - Exclusion: pregnant during the study period, were converted to a non-tacrolimus immediate release product, or had less than two tacrolimus trough levels during the defined observation periods

- Patients were divided into four separate groups: Group A) innovator tacrolimus (no conversion), Group B) single generic tacrolimus formulation (no conversion), Group C) single tacrolimus conversion (from innovator to generic or from generic to innovator), and Group D) multiple tacrolimus conversions between formulations

- Patients in the control arms of the study (i.e. Groups A and B) were assigned an index date for evaluation, which was selected to match time to conversion post-transplantation in the conversion arms (i.e. Groups C and D). Index dates in the conversion arms were defined as the date of first tacrolimus conversion

- Patient data was collected 420 days before and after the index date. To balance the data for statistical analysis, laboratory information was grouped into the following time intervals before and after the index date: 0 – 60 days, 61 – 180 days, 181 – 300 days, and 301 – 420 days. For each time interval, if there were multiple laboratory levels for a patient, the most time-centric set of values and clinical information was selected.

- Groups were compared using the Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. Linear trend was estimated for dose-normalized tacrolimus levels, eGFR, and serum creatinine using regression models with terms allowing for differing slopes within each period and within each group. SAS software (version 9.4, SAS Institute, Cary, NC) was utilized for all statistical analysis.

Results

TABLE 1. Patient demographics and baseline immunosuppression

Variable	Group A (n=29)	Group B (n=19)	Group C (n=26)	Group D (n=26)	p-value
Age (years) at transplant, median (IQR)	48.4 (42.0, 58.7)	49.9 (38.6, 60.2)	50.5 (42.2, 60.6)	49.3 (44.5, 56.5)	0.97
Male, n (%)	19 (65.5)	8 (42.1)	15 (57.7)	21 (80.7)	0.06
African American, n (%)	9 (31.0)	7 (36.8)	11 (42.3)	11 (42.3)	0.78
DM (at index date), n (%)	12 (41.4)	6 (31.6)	12 (46.2)	9 (34.6)	0.75
Hypertension (at index date), n (%)	20 (71.4)	15 (78.9)	23 (88.5)	23 (88.5)	0.22
High immunologic risk**, n (%)	13 (44.8)	10 (52.6)	11 (42.3)	12 (46)	0.92
Hemoglobin A1c, median (%)	5.9 (5.3,7.2) n=25	5.3 (5.0,6.0) n=19	5.8 (5.4,6.9) n=26	5.8 (5.3,6.2) n=25	0.23
Reason for transplant, n (%)					
Diabetes Mellitus	8 (27.6)	4 (21.1)	8 (30.7)	5 (19.2)	
Hypertension	2 (6.9)	4 (21.1)	3 (11.5)	5 (19.2)	
FSGS	2 (6.9)	1 (5.3)	2 (7.7)	3 (11.5)	-
Alcoholic Cirrhosis	2 (6.9)	1 (5.3)	1 (3.8)	1 (3.8)	
Hepatitis C virus	3 (10.3)	1 (5.3)	3 (11.5)	1 (3.8)	
Other	12 (41.4)	8 (42.1)	9 (34.6)	11 (42.3)	
Transplant Type, n (%)					
Living kidney	6 (20.7)	9 (47.4)	6 (23.1)	8 (30.7)	
Deceased kidney	6 (20.7)	5 (26.3)	5 (19.2)	14 (53.8)	
Liver	10 (34.5)	4 (21.1)	7 (26.9)	2 (7.7)	
Heart	2 (6.9)	0 (0)	2 (7.7)	0 (0)	
Pancreas	2 (6.9)	1 (5.3)	0 (0)	0 (0)	0.025
Kidney/heart	0 (0)	0 (0)	1 (3.8)	0 (0)	
Kidney/Pancreas	3 (10.3)	0 (0)	4 (15.4)	2 (7.7)	
Liver/ Kidney	0 (0)	0 (0)	1 (3.8)	0 (0)	
Median HLA mismatches, (IQR)	3 (2, 4) n=13	3.5 (2, 5) n=12	5 (4, 5) n=14	4 (3, 5) n=23	0.12
Peak PRA > 25%, n (%)	2 (13.3) n=15	0 (0) n=14	0 (0) n=15	1 (4) n=23	-
Patients with DGF, n (%)	3 (20) n=15	0 (0) n=14	1 (6) n=16	1 (4) n=24	0.24
Repeat Transplant, n (%)	6 (20.7)	3 (15.8)	2 (7.7)	1 (3.8)	0.23
Time post-transplant at index date (years), median (IQR)	3.7 (2.6, 7.5)	5.0 (2.1, 7.2)	7.6 (3.4, 9.1)	5.2 (3.0, 8.8)	0.31

*No statistically significant pairwise comparisons were identified using the Hochberg approach

**High immunologic risk defined as African American race, peak PRA>25%, or repeat transplant.

TABLE 2. Tacrolimus dose adjustments by patient group post-index date

Dose changes after conversion/ index date	Group A (n=29)	Group B (n=19)	Group C (n=26)	Group D (n = 26)	p-value
Decrease tacrolimus only, n (%)	8 (28)	3 (16)	3 (12)	4 (15)	
Increase tacrolimus only, n (%)	1 (3)	2 (11)	4 (15)	6 (23)	
Both Increase and decreases in tacrolimus, n (%)	1 (3)	3 (16)	5 (19)	3 (12)	0.32
No tacrolimus dose change, n (%)	19 (66)	11 (58)	14 (54)	13 (50)	

TABLE 3. Tacrolimus dose changes pre- versus post-index date

	Pre-index date	Post-index date	p-value
Group A (n = 29)			
Percent of patients with dose change, n (%)	13 (45)	10 (34)	0.37
Number of dose changes per patient, median (range)	0 (0, 12)	0 (0, 4)	0.03
Absolute value of the maximum dose change, median mg (IQR)	0 (0, 2)	0 (0,1)	0.34
Percent of patients with tacrolimus dose changes within 30 days of conversion/ index date	-	0 (0)	-
Group B (n = 19)			
Percent of patients with dose change, n (%)	10 (53)	8 (42)	0.48
Number of dose changes per patient, median (range)	1 (0, 7)	0 (0, 5)	0.45
Absolute value of the maximum dose change, median (IQR)	1 (0, 5)	0 (0, 2)	0.13
Percent of patients with tacrolimus dose changes within 30 days of conversion/ index date	-	0 (0)	-
Group C (n = 26)			
Percent of patients with dose change, n (%)	10 (38)	12 (46)	0.41
Number of dose changes per patient, median (range)	1 (0, 4)	0 (0, 3)	0.89
Absolute value of the maximum dose change, median (IQR)	0 (0, 2)	0 (0, 1.5)	0.69
Percent of patients with tacrolimus dose changes within 30 days of conversion/ index date	-	0 (0)	-
Group D (n = 26)			
Percent of patients with dose change, n (%)	12 (46)	13 (50)	0.78
Number of dose changes per patient, median (range)	0 (0, 10)	0 (0, 7)	0.66
Absolute value of the maximum dose change, median (IQR)	0 (0, 2)	0.25 (0, 2)	0.76
Percent of patients with tacrolimus dose changes within 30 days of conversion/ index date	-	1 (4)	-

TABLE 4. Patient biopsies and rejection episodes pre- versus post-index date

Variables	Pre- index date	Post- index date
Group A (n = 29)		
Number of patients who underwent biopsy, n (%)	7 (24)	3 (10)
Biopsies with rejection, n (%)	11/19 (56)	2/3 (67)
Group B (n = 19)		
Number of patients who underwent biopsy, n (%)	6 (32)	2 (11)
Biopsies with rejection, n (%)	6/10 (60)	3/4 (75)
Group C (n = 26)		
Number of patients who underwent biopsy, n (%)	3 (12)	4 (15)
Biopsies with rejection, n (%)	0/3 (0)	2/4 (50)
Group D (n = 26)		
Number of patients who underwent biopsy, n (%)	4 (15)	1 (4)
Biopsies with rejection, n (%)	2/5 (40)	0/1 (0)

TABLE 5. Patient hospitalizations pre- versus post-index date

Variables	Pre-index date	Post-index date	p-value
Group A (n = 29)			
Patients with hospitalizations, n (%)	13 (45)	10 (35)	0.26
Patients with multiple hospitalizations, n (%)	4 (14)	5 (17)	0.56
Group B (n = 19)			
Patients with hospitalizations, n (%)	8 (42)	6 (32)	0.41
Patients with multiple hospitalizations, n (%)	3 (16)	2 (11)	0.56
Group C (n = 26)			
Patients with hospitalizations, n (%)	8 (31)	6 (23)	0.48
Patients with multiple hospitalizations, n (%)	4 (15)	2 (8)	0.32
Group D (n = 26)			
Patients with hospitalizations, n (%)	7 (27)	6 (23)	0.66
Patients with multiple hospitalizations, n (%)	3 (12)	4 (15)	0.32

FIGURE 1.

Changes in dose-normalized tacrolimus trough levels by patient group pre- and post-index date

Group A: p = 0.39
Group B: p = 0.007
Group C: p = 0.83
Group D: p = 0.33

FIGURE 2.

Changes in estimated glomerular filtration rate by patient group pre- and post-index date

Group A: p = 0.88
Group B: p = 0.11
Group C: p = 0.27
Group D: p = 0.69

Conclusion

Overall, this study demonstrated that conversion of tacrolimus to an alternative product did not result in statistically significant differences in dose-normalized tacrolimus trough concentrations, tacrolimus dose adjustments, or renal function. Additionally, other surrogate markers for adverse events (i.e. hospitalizations and rejection episodes) were similar across the pre- and post-index date study periods.

Limitations:

- Patients who transferred their tacrolimus prescriptions outside of the closed pharmacy system were excluded.
- Patients had variable laboratory follow-up due to individual allograft and time-post transplantation differences across patients.

References

1. Prograf(R) [package insert]. Astellas Pharma US, Inc., Northbrook, IL. May 2015 [December 6, 2016]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050708s045,050709s038lbl.pdf.
2. U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Tacrolimus. 2016 [cited 2016 July 1]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=065461.
3. U.S. Food And Drug Administration. Guidance for Industry - Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA 2013 [cited 2017 March 20]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm377465.pdf.
4. U.S. Food and Drug Administration. Draft Guidance on Tacrolimus 2014 [cited 2017 July 28]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM181006.pdf.
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics. 2004;43(10):623-53.
6. Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant. 2012;12(10):2825-31.
7. McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S. A multicenter experience with generic tacrolimus conversion. Transplantation. 2011;92(6):653-7.
8. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant. 2011;11(9):1861-7.
9. Spence MM, Nguyen LM, Hui RL, Chan J. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Pharmacotherapy. 2012;32(11):981-7.

"The opinions expressed in this presentation are those of the authors and may not reflect the position of the U. S. Food and Drug Administration."